ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2015

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.

Nadja Müller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.